dihydroergocryptine has been researched along with bromocriptine in 5 studies
Studies (dihydroergocryptine) | Trials (dihydroergocryptine) | Recent Studies (post-2010) (dihydroergocryptine) | Studies (bromocriptine) | Trials (bromocriptine) | Recent Studies (post-2010) (bromocriptine) |
---|---|---|---|---|---|
5 | 0 | 2 | 7,121 | 727 | 499 |
21 | 8 | 2 | 7,121 | 727 | 499 |
Protein | Taxonomy | dihydroergocryptine (IC50) | bromocriptine (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.532 | |
Beta-1 adrenergic receptor | Homo sapiens (human) | 2.4 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 2.4996 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.015 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.0016 | |
Androgen receptor | Rattus norvegicus (Norway rat) | 2.281 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.035 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.52 | |
D | Rattus norvegicus (Norway rat) | 0.0279 | |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0056 | |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
D(1A) dopamine receptor | Homo sapiens (human) | 2.889 | |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.03 | |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.036 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.532 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0056 | |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.0006 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0083 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.022 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dantzig, AH; Ekins, S; Kim, RB; Lan, LB; Leake, BF; Schuetz, EG; Schuetz, JD; Shepard, RL; Wikel, JH; Winter, MA; Wrighton, SA; Yasuda, K | 1 |
Furuya, K; Lan, LB; Sanglard, D; Schuetz, EG; Schuetz, JD; Yasuda, K | 1 |
Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
Lee, MR | 1 |
Bernard, N; Descotes, J; Gillet, A; Gouraud, A; Mirkou, A; Suchovsky, D; Vial, T | 1 |
1 review(s) available for dihydroergocryptine and bromocriptine
Article | Year |
---|---|
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
4 other study(ies) available for dihydroergocryptine and bromocriptine
Article | Year |
---|---|
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Ergonovine; Fluoxetine; Humans; Models, Molecular; Oxytocics; Protein Conformation; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Swine; Transfection; Vinblastine | 2002 |
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dihydroergocryptine; Drug Interactions; Enzyme Inhibitors; Fluconazole; Humans; Mice; Mice, Knockout; Microsomes, Liver; Oxidoreductases, N-Demethylating; Recombinant Proteins; Reserpine; Swine; Tissue Distribution; Transfection; Vinblastine | 2002 |
The history of ergot of rye (Claviceps purpurea) III: 1940-80.
Topics: Bromocriptine; Claviceps; Dihydroergocryptine; Ergot Alkaloids; History, 20th Century; Humans; Lysergic Acid Diethylamide; Parkinson Disease; Prolactinoma; Receptors, Dopamine; Schizophrenia; Scotland; Secale | 2010 |
[Prescription of ergot derivatives for lactation inhibition in France: Current practices].
Topics: Bromocriptine; Cabergoline; Dihydroergocryptine; Dopamine Agonists; Ergolines; Ergot Alkaloids; Female; France; Humans; Lactation; Lisuride; Practice Patterns, Physicians'; Prolactin; Surveys and Questionnaires | 2012 |